In vivo efficacy data will be presented for two lead therapeutic programs in development to treat rare genetic metabolic disorders   CAMBRIDGE, Mass. – June 11, 2015  – Synlogic, Inc., a biotechnology company pioneering the development of therapeutic synthetic life, today announced that...

Accomplished drug hunter takes helm of synthetic biology leader as company advances lead therapeutic microbe programs toward clinical testing and executes path to drug discovery platform expansion Company debuts rare disease focused pipeline with two programs directed at genetic metabolism...

Bill & Melinda Gates Foundation Joins Previously Announced Series A Financing Paul Miller Ph.D. and Alison Silva join Synlogic Leadership Team CAMBRIDGE, Mass. – October 7, 2014  – Synlogic, Inc., a biotechnology company focused on the development of therapeutic microbes, today announced...

First-in-class, proprietary synthetic biology platform leveraged for application across multiple diseases CAMBRIDGE, Mass. – July 22, 2014  – Synlogic, Inc., a biotechnology company focused on the development of therapeutic microbes, today announced the company raised $29.4 million in a Series...